The Weekly Summary

Ebola-patient-mapOctober 6th – October 12th

In the general news, global Ebola fears dominated the news, from Africa to Spain to Dallas, where a patient died, then a nurse caring for him also became infected.

In healthcare business news, Becton Dickinson (BDX) acquired CareFusion (CFN) for $12 B. Endo International acquired Auxilium (AUX) as part of a tax-reduction inversion deal. Also, Actavis (ACT) made a move to acquire Allergan (AGN) as the Valeant (VRX) attempt stalls.

From the FDA, a third FDA panel. once again, recommend approval of the Boston Scientific (BSX) left atrial occlusion device called Watchman. The Bard (BCR) Lutonix drug coated balloon to treat peripheral vascular disease was approved. Salix’s (SLXP) foam delivery of drug Uceris (budesonide) to treat ulcerative colitis was approved. Eisai’s drug Akynzeo for nausea was approved. Regeneron (REGN) received a label expansion for Eylea to treat retinal vein occlusion macular edema, and Gilead’s (GILD) combo pill Harvoni (ledipasvir and sofosbuvir) was approved.

In other regulatory news, Senator Bernie Sanders and Rep. Elijah Cummings launched an investigation into price gouging by generic drug companies. Also, The White House and the CDC prepared plans to treat Ebola patients in remote hospitals away from urban areas as the military put boots on the ground in Africa to help stem the source of the outbreak.

This entry was posted in - The Weekly Summary. Bookmark the permalink.

Leave a Reply

Your email address will not be published.